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SUMMARY 
Beta-lactamase inhibitors are clinically proven to revitalise old beta-lactam antibiotics by 
neutralising bacterial beta-lactamases. We call these compounds antibiotic resistance breakers. 
Unfortunately, bacteria express more than 1000 beta-lactamases, of which the metallo-beta-
lactamases are proving difficult to neutralise. Here we describe other antibiotic resistant 
breakers, which are not yet in the clinic, but which potentially revitalise other classes of 
antibiotics. These include aminoglycoside modifying enzyme inhibitors, efflux pump 
inhibitors and compounds which are associated with increased permeability of the bacterial 
cell membrane. If it were possible to develop new antibiotic resistant breakers for many 
different classes of antibiotics, this approach could be a viable alternative to the more expensive 
single novel compound route which has been pursued for pyogenic bacterial infections.  
 
INTRODUCTION  
Antibiotic resistance develops to all antibiotics [1, 2, 3]. Over several decades, this leads to the 
need to replace old antibiotics with new ones. Unfortunately, the world has not produced 
antibiotics fast enough to cope with the emergence of antibiotic resistance, particularly for 
Gram-negative bacteria [4]. Between the 1940s and 1970s, the “Golden era”, about 20 new 
classes of antibiotics were produced, which led to more than 200 analogues. Since then, there 
have only been three new classes marketed, none of which are for Gram-negatives [5]. Can we 
recreate the Golden era? In other words, can we make 20 new classes of antibiotics which are 
active against highly resistant bacteria? There is much debate about this. Whilst new antibiotics 
against Gram-positive bacteria have been marketed in recent years, the main problem is that 
resistant Gram-negative bacteria are poorly served, with no new class being marketed for 40 
years [5]. Furthermore, new antibiotics which are effective against the carbapenem resistant 
bacteria [6], which express, for example NDM-1 [7]  are not being introduced into the market 
in good time, and we are playing ‘Catch-up’. 
Is there a way forward? On the one hand, if enough money was provided by governments, 
perhaps in a similar way to the Marshall plan [8,9], or the   Public Health Emergency Medical 
Countermeasures Enterprise [10] which is a public-private partnership of  multiple agencies of 
the US Federal Government, many more antibiotics might reach the market.  
This would need to be accompanied by global efforts by non-profit organisations such as the 
Bill & Melinda Gates Foundation, the Drugs for Neglected Diseases Initiative (a  research and 
development organization which develops new treatments for neglected diseases) and 
Medicines for Malaria Venture, which is a public–private partnership with aim of providing 
affordable antimalarial drug discovery and development. In addition, there would need to be  
changes in regulation, and encouragements for industry, for example the Generating 
Antibiotics Incentives Now (GAIN) Act in USA, and the proposed  Antibiotic Development to 
Advance Patient Treatment Act in USA (“ADAPT Act”) for a Limited Population 
Antimicrobial Drug Pathway [8, 11].   
On the other hand, in the long term, it may not be possible to market enough antibiotics to keep 
up with the relentless emergence of antibiotic resistance [12,13]. Whilst prevention will clearly 
play a greater role, this will not substitute for new antibiotics. The existing strategy is to 
discover and develop novel single antibiotic therapy[14]. Do we need to rethink this strategy?  
Considering costs alone, if we intend to discover and develop 200 new antibiotics, the cost will 
be somewhere in excess of $1 billion per compound [15].  So this route would be very 
expensive. Is it scientifically feasible to endlessly produce more and more antibiotics? The past 
40 years have shown that it is becoming more difficult to bring new antibiotics to the market. 
The absence of new classes of antibiotics for Gram-negative infections during this period is an 
important example[5]. Now we have virtually untreatable carbapenem resistant Gram-negative 
infections, exemplified by those bacteria which express metallo-beta-lactamase (MBL) [7], for 
which we are using, as a last resort,  colistin [16], itself an old, relatively toxic antibiotic. 
Colistin resistance is now emerging in MBL Enterobacteriaceae [17]. Furthermore, the 
development of novel antibiotics against MBL resistant bacteria is still in early clinical 
development [14,18]. In addition, we know that antibiotic resistance arises to all antibiotics 
within a few years after entry into the marketplace [19]. Therefore a continuous flow new 
antibiotics into the market is needed. It seems unlikely that the world will be able to produce a 
limitless number of antibiotics far into the future. If the supply of effective antibiotics dries up, 
modern medicine is likely to suffer a devastating set back [13, 20]. 
We propose a new strategy. The world should revitalise conventional antibiotics by combining 
them with antibiotic resistance breakers (ARBs). This approach would mean that we could, 
potentially, continue to use conventional antibiotics. This has the advantage of being a cheaper 
option than developing hundreds of new antibiotics. For example, if each class of antibiotics 
could be resuscitated by a single antibiotic resistance breaker, theoretically, most of the 200 
existing antibiotics could become useful again. Potentially, this could be achieved with many 
fewer new compounds than would be required for the replacement of the existing 200 
compounds. There would be substantial financial savings and this would transform the 
feasibility of prolonging the Antibiotic Era.   This chapter looks at the origins of combination 
antibiotic therapy and examines whether it is possible to extend this concept, namely the 
combination of conventional antibiotics (see Table 1) with resistance breakers, thereby 
revitalising a wide range of different classes of antibiotics.  
 
CONVENTIONAL ANTIBIOTICS  
 
The main classes of antibiotics which have been marketed, and many of their analogues, are 
listed in Table 1. Resistance has occurred to all of them. The β-Lactams are degraded by 
bacterial β-Lactamases which can be neutralised by combining the old antibiotic with a β-
Lactamase inhibitor such as clavulanic acid [21]. This will be discussed in more detail in the 
next section, as will other combinations. Potential combinations only exist for a minority of 
classes.  
 
Table 1 | Main classes of antibiotics  
 
Class Examples 
 
Aminoglycosides  Streptomycin, neomycin, kanamycin, paromycin, gentamicin, 
tobramycin, amikacin, netilmicin, spectinomycin, sisomicin, 
dibekalin, isepamicin 
 
β-Lactams 
    Penicillins Penicillin G, penicillin V, methicillin, oxacillin, cloxacillin, 
dicloxacillin, nafcillin, ampicillin, amoxicillin, carbenicillin, 
ticarcillin, mezlocillin, piperacillin, azlocillin, temocillin 
    Cephalosporins 
First generation Cepalothin, cephapirin, cephradine, cephaloridine, cefazolin 
Second generation Cefamandole, cefuroxime, cephalexin, cefprozil, cefaclor, 
loracarbef, cefoxitin, cefmetazole 
Third generation Cefotaxime, ceftizoxime, ceftriaxone, cefoperazone, 
ceftazidime, cefixime, cefpodoxime, ceftibuten, cefdinir 
Fourth generation Cefpirome, cefepime 
    Carbapenems Imipenem, meropenem 
    Monobactams Astreonam 
 
β-Lactamase Inhibitors Clavulanate, sulbactam, tazobactam 
 
Glycopeptides Vancomycin, teicoplanin 
 
Macrolides Erythromycin, azithromycin, clarithromycin 
 
Metronidazole 
 
Lincosamides Lincomycin, clindamycin 
 
Lipopeptides Daptomycin 
 
Oxazolidinones Linezolid 
 
Polymyxin Polymyxin B, Polymyxin E (colistin) 
 
Quinolines Bedaquiline 
 
Quinolones Nalidixic acid, oxolinic acid, norfloxacin, pefloxacin, 
enoxacin, ofloxacin/levofloxacin, ciprofloxacin, 
temafloxacin, lomefloxacin, fleroxacin, grepafloxacin, 
sparfloxacin, trovafloxacin, clinafloxacin, gatifloxacin, 
moxifloxacin, sitafloxacin 
 
Rifamycins Rifampicin (also called rifampin), rifapentine, rifabutin, 
bezoxazinorifamycin, rifaximin 
 
Streptogramins Quinupristin, daflopristin 
 Sulphonamides Sulphanilamide, para-aminobenzoic acid, sulfadiazine, 
sulfisoxazole, sulfamethoxazole, sulfathalidine 
 
Tetracyclines Tetracycline, chlortetracycline, demeclocycline, minocycline, 
oxytetracycline, methacycline, doxycycline, tigecycline 
 
Trimethoprim 
 
  
THE PRINCIPLES OF COMBINATION ANTIBIOTIC THERAPY 
In the clinic, combinations of antibiotics are often used. The main reasons for such 
combinations are:  
1. Combinations which break resistance and rejuvenate old antibiotics. The best 
example of this approach is the combination of clavulanic acid and amoxicillin [21]. 
Clavulanic acid inhibits bacterial beta-lactamase which neutralises amoxicillin, thus 
allowing the latter to kill beta-lactamase producing bacteria.   Clavulanic acid alone 
has no anti-bacterial activity. This chapter primarily deals with breaking resistance.  
2. To prevent the emergence of resistance during chemotherapy. It is important to 
appreciate the limitations of this approach. Whilst combinations of antibiotics do 
prevent the emergence of resistance during tuberculosis chemotherapy [22], it is 
unlikely that this will be effective in multi-species environments such as the large 
intestine. In the case of Mycobacterium tuberculosis, combinations are effective 
because mutations only arise in the chromosome, and do not occur due to plasmid 
transfer from other species of bacteria[23]. M. tuberculosis lives on its own in a 
relatively sterile environment, for example inside macrophages in the lung. So there 
is little opportunity for plasmid transfer. Resistance due to transfer of plasmids does 
not occur in M. tuberculosis.  In contrast, other bacteria, such as Escherichia coli,  
live in the large intestine in a multi-species environment where resistance is often 
transferred via plasmids [24]. Combinations such as  sulphonamide and 
trimethoprim(co-trimoxazole) already have high levels of resistance- for example, 
over 95% of Gram-negative bacteria from babies in  rural India [25]  in spite of 
early hopes that such a combination would prevent the emergence of resistance [26]. 
A meta-analysis (including data from eight randomised controlled trials) that 
compared aminoglycoside/beta-lactam combination therapy with beta-lactam 
mono-therapy to observe the emergence of antimicrobial resistance found that 
aminoglycoside/beta-lactam combination therapy was not associated with a reduced 
development of resistance when compared with beta-lactam therapy alone [27]. 
Nevertheless, for certain infections, where chromosomal resistance is thought to be 
important, combinations of different antibiotics may have the potential to prevent 
the emergence of resistance. 
 
3. Combinations in which one antibiotic boosts the effect of a second antibiotic and 
visa-versa. This is called synergy.  For instance,  penicillin and gentamicin are 
synergistic [28], and  are used to treat bacterial endocarditis.  
4. A combination of antibiotics is used by clinicians to broaden the number of species 
of bacteria which are targeted. For example, if a seriously ill patient has suspected 
intra-abdominal infection with an unknown bacterium, an aminoglycoside and anti-
anaerobe agents can be used [29]. 
5. Sometimes, the clinician may be faced with an infection which harbours dormant 
bacteria as well as fast multiplying ones. Tuberculosis is well known as an infection 
which persists due to the presence of dormant bacteria which are relatively tolerant 
to antibiotics. Combinations of antibiotics, typically containing four separate 
compounds (Rifampicin, pyrazinamide, isoniazid and ethambutol), are used in the 
initial stages of tuberculosis therapy. Rifampicin and pyrazinamide kill dormant 
bacteria and so are responsible for the shortening of the duration of chemotherapy 
from 12 to 6 months [22].  
 
.  
     
 
ANTIBIOTIC RESISTANCE BREAKERS 
REVITALISE CONVENTIONAL ANTIBIOTICS 
             The main threat to the effectiveness of a marketed antibiotic is the emergence of 
widespread resistance amongst its bacterial targets. Whilst prevention of resistance is clearly 
the ultimate answer to this problem, the world is a long way from reversing this trend. Since 
resistance to an antibiotic is an inevitable consequence of entry into the market, the main 
subject of this chapter is to examine the feasibility of revitalising conventional antibiotics by 
the addition of an antibiotic resistance breaker. The combination is active against resistant 
bacteria.  In the large pyogenic bacterial field, combination therapy has not been developed to 
the extent that it has in tuberculosis, although, HIV and cancer therapy do use well 
characterised combinations of drugs.   
There are a number of ways that conventional antibiotics can be revitalised by 
combining them with another agent.   
1.  Beta-Lactamase Inhibitors.    
Bacteria can produce beta-lactamases, which are enzymes that destroy the beta-lactam ring of 
beta-lactam antibiotics, thereby reducing their effectiveness [30]. There are over 1300 known 
beta-lactamases. The concept of combining a beta-lactam antibiotic with a beta-lactamase 
inhibitor in order to revitalise the antibiotic and to render it active against beta-lactamase 
expressing bacteria, was first introduced into the market by the   combination of the  beta-
lactamase inhibitor clavulanic acid, derived from Streptomyces calvuligerus, with amoxicillin 
[31]. This combination is called Augmentin(GlaxoSmithKline, Brentford, UK). In a clinical 
trial [32] patients with non-bullous  impetigo were treated with either amoxicillin alone or 
Augmentin.  The causative organism of impetigo, Staphylococcus aureus was shown to be 
present in lesions from all the patients. When tested for sensitivity to amoxicillin, all the 
bacterial isolates were resistant, but were sensitive to Augmentin.  Clinically, the Augmentin 
group of patients responded better than the amoxicillin group. These data indicated that 
neutralisation of bacterial beta-lactamase can revitalise amoxicillin.  
Unfortunately, bacteria produce many beta-lactamases which are not inhibited by clavulanic 
acid. There has been a 100 fold increase in the number of known beta-lactamase inhibitors in 
the past 40 years [30].  The classification of bacterial beta-lactamases is complicated. We have 
used the Bush (2013) system in this paper, bearing in mind that Extended Spectrum Beta-
Lactamases (ESBLs which include TEM and SHV) and carbapenemases(such as NDM and 
KPC) in Gram-negatives are thought to be of the greatest clinical importance because they are 
difficult to treat and are relatively common in many countries [33,34].  Beta-lactamases can be 
divided into Ser- and Metallo-beta-lactamases, by their active sites. They are sub-divided into 
Molecular Classes A-D, which have Functional groups and Major functional subgroups. For 
example, the Serine beta-lactamases Molecular class C 1(1,1e) which degrade early 
cephalosporins and expanded spectrum cephalosporins in the case of 1e, Class A 2 
(2a,2b,2be,2br,2f) which degrade penicillins and others, and in the case of 2f, penicillins, early 
and expanded spectrum cephalosporins, carbapenems and monobactams, and Class D 2d(2de, 
2df) which destroy penicillins and in the case of 2df, carbapenems. The Metallo-beta-
lactamases B 3 (3a and 3b)  target carbapenems, and in the case of 3a, penicillins and early and 
expanded spectrum cephalosporins. Enzymes which are expressed are C 1(AmpC, CMY) and 
1e(GC1), A 2a(PC1), 2b(TEM-1, SHV-1), 2be(CTX-M, ESBLs(TEM, SHV)), 2br(IRT, SHV-
10), 2f(KPC,SME), 2de(OXA-11, OXA-15), 2df(OXA-23, OXA-48), and B 3a(IMP, VIM, 
NDM), 3b (CphA).   
Clavulanic acid only neutralises the Serine beta-lactamases A(2a, 2b and 2be) and has a partial 
effect on A(2f), and D(2d). Clavulanic acid has also been combined with ticarcillin (Timentin; 
GlaxoSmithKline, Brentford, UK). Other inhibitor combinations include tazobactam with 
piperacillin (Zosyn; Pfizer, Philadelphia, PA, USA), and sulbactam with ampicillin (Unasyn; 
Pfizer, Philadelphia, PA, USA).  Unfortunately, the current beta-lactamase inhibitor 
combinations are not active against bacteria which express AmpC or ESBLs. Even worse [35], 
is that, so far, it is proving difficult to develop  Metallo-beta-lactamase inhibitors which are 
effective against NDM.  
Since the current marketed inhibitors are only active against class A enzymes but lack 
effectiveness against class A KPC carbapenemases, new inhibitors are under development 
which broaden the beta-lactamases which can be neutralised. For example, avibactam which is 
a bridged 1,6-diazabicyclo[3.2.1]ocatan-7-one (DBO) is in clinical development. This 
compound is active against a wide range of Class A and C serine b-lactamases [36], including 
ESBLs and class A carbapenemases. Although it neutralises Class D OXA-48, it is inactive 
against other D carbapenemases.  This molecule also inhibits selected class D b-lactamases 
including OXA-48, but  not other class D carbapenemases or B metallo-beta-lactamases. 
Avibactam combinations with ceftaroline (Cereza-Forest) and cefdazidime(AstraZeneca and 
Forest)  are in clinical trials [35].  
Another combination under development(Cubist) is tazobactam and   ceftolozane [37]. 
Tazobactam increases the activity of the combination against 
ESBL-producing Enterobacteriaceae, and can partially neutralise AmpC and KPC 
carbapenemases. 
A new DBO (MK-7655 Merck)  has been combined with imipenem, and is in clinical trials 
[38]. This combination is active against KPC-2-producing  K. pneumoniae and  AmpC-
overexpressing isolates of P. aeruginosa  but not those which express metallo-carbapenemases 
[39].  
 
  
  
 
.  
2. Aminoglycoside-modifying  enzyme inhibitors.  Whilst these type of inhibitors have 
not yet reached the clinical trials phase of development, some interesting in vitro 
experience has been achieved. In general, inhibitors of aminoglycoside-modifying 
enzymes [40,41] have struggled with numerous different targets because bacteria may 
express multiple enzymes. However, inhibition of aminoglycoside 
phosphotransferases and acetyl transferases has been shown by cationic antimicrobial 
peptides [40]. Indolicidin is a bovine antimicrobial peptide. This peptide and its 
synthetic analogues inhibited both aminoglycoside phosphotransferase and 
aminoglycoside acetyltransferase classes. This is the first description of broad-
spectrum inhibitors of aminoglycoside resistance enzymes. Crystallography studies 
have shed light on the molecular structure of aminoglycosidephosphotransferases or 
kinases(APHs). A review of APH structures and inhibitors is covered by Shi and 
colleagues [42]. These data suggest that the commercial development of a universal 
APH inhibitor may not be feasible.    
3. Antibiotic efflux pump inhibitors          Although there are numerous examples of 
antibiotic efflux pump inhibitors, none are in clinical trials as yet.  
The main families of bacterial efflux pumps which are chromosomally expressed and 
which are associated with multi-drug resistance [43], are the resistance nodulation 
division (RND) family(encodes AcrA/B-TolC), the major facilitator superfamily 
(MFS)(encodes QacA), and the staphylococcal multiresistance (SMR)(encodes QacC), 
the multidrug and toxic compound extrusion (MATE) family(NorM) and the ABC 
(ATP binding cassette)(LmrA). Efflux pump inhibitors include reserpine [44]   which 
is too neurotoxic to be used at effective  concentrations in humans [45],  berberine and 
palmatine [46],  and other compounds (reviewed in [43]) including plant extracts, 
synthetic molecules,  thioxanthenes, phenothiazenes, and arylpiperazines. Whist some 
inhibitors perform well in vitro, problems with toxicity have not resulted in extensive 
clinical trials. In addition, particularly in some Gram-negative bacteria, treatment with 
an inhibitor may lead to compensatory upregulation of other efflux pumps.  For 
example [47], RamA expression is induced by inhibition of efflux or inactivation of 
acrAB in Salmonella typhimurium.  
 
4. Synergy associated with bacterial membrane permeators  
Synergy  between non-antibiotics and antibiotics, and between antibiotics themselves 
is well-known. In some cases this synergy is associated with one of the pair in the 
combination being a bacterial membrane permeabiliser. Whether this is responsible for 
the synergy is unknown in many cases, but it has been suggested [48]  that 
permeabilisation of the membrane may increase the intracellular concentration of the 
antibiotic in the combination, and this, in turn may increase the anti-bacterial potency 
of the antibiotic.   Some of these associations are described here.   
Gram-negative bacteria have two membranes. In the case of fluoroquinolones, outer 
membrane proteins play a key part in helping these molecules to cross the membrane 
[49,50]. In contrast, passive diffusion is thought to be important for translocation of 
the inner membrane of Gram-negatives and the single membrane of Gram-positives 
[51,52,53,54]. In the 1960s [55,56]  improved penetration of fluoroquinolones was  
achieved by the addition of a 7-piperazine side-chain and this is thought initiate  
translocation across the membrane [57]. This suggests that adding side-groups  such 
as piperazine or membrane permeabilisation compounds in combinations could be a 
way of increasing the activity of current antibiotics.   
One of the most serious problems in clinical practice in the world, is the emergence of 
carbapenem resistant Gram-negative bacteria. Carbapenems are often used as the 
antibiotics of last resort.  Combinations of antibiotics are used to treat patients with 
carbapenem resistant metallo-beta-lactamase producing Gram-negative infections 
such as  Klebsiella pneumoniae [58], and these combination often contain colistin. This 
antibiotic, which is a polypeptide of the polymyxin group, increases the permeability 
of Gram-negative membranes [59]. The polycationic regions of colistin displace the 
bacterial counter ions in the lipopolysaccharide of the outer membrane. The inner 
membrane is solubilised by the hydrophobic/hydrophilic regions of colistin.  Whilst 
clinical data regarding the efficacy of different antibiotic combinations is sparse, in 
vitro data [58]  suggests that a combination of colistin, rifampicin and meropenem is 
effective against metallo-beta-lactamase producing K. pneumonia(VIM; NDM-1). 
Antimicrobial peptides can also increase the permeability of bacterial membranes, and 
can synergise with conventional antibiotics. For example [60]  antimicrobial peptides 
have been created which synergise with conventional antibiotics such as cefotaxime, 
ciprofloxacin or erythromycin  against highly resistant strains of the  Gram-negative 
bacterium Acinetobacter baumannii. There are three models of AMP membrane 
interaction(Reviewed in [61]): Barrel-stave pores, toroidal pores and carpet 
mechanism in which peptides form a layer on the surface and dissolve the membrane 
[62]. AMPs have numerous other effects on bacterial cells, and so synergy may not 
necessarily be the most important as far as a bactericidal effect is concerned.  
A recent development has been the observation of enhancement or synergy between a 
compound which was developed against dormant Staphylococcus aureus [63] and 
three different classes of antimicrobials [64]. The compound (HT61; Helperby 
Therapeutics Ltd, London) depolarises the bacterial cell membrane and is in clinical 
trials.  
Another example is Loperamide (Immodium; McNeil Consumer Healthcare, Fort 
Washington, PA, USA) [65] is an opioid receptor agonist which enhances the activity 
minocycline against Escherchia coli, S aureus and Pseudomonas aeruginosa. 
Loperamide interferes with the electrical component of the proton motive force of the 
bacterial membrane. This leads to an increase in the pH gradient which enhances the 
entry of tetracycline into the cell.  
 
DISCUSSION  
Revitalising old antibiotics by combination with a second compound  means that resistance to 
the old antibiotic is broken by the second compound, either directly or indirectly. 
There is only one clear, clinically proven example of rejuvenation of old antibiotics in this way, 
namely the addition of beta-lactamase inhibitors to beta-lactams.   Arguably, the addition of 
the 7-piperazine ring to quinolones in order to enhance the initiation of translocation, could be 
regarded as another example.  Antibiotic-antibiotic combinations which are frequently used in 
clinical practice, for example in tuberculosis chemotherapy, do not break resistance as such. 
Such antibiotic-antibiotic combinations (with the exception of those which include colistin, 
and perhaps other membrane permeators) have other functions such as preventing the 
emergence of resistance (tuberculosis chemotherapy), or synergy(increasing efficacy).  If 
resistance exists to the primary antibiotic, a second antibiotic is added to which the organism 
is sensitive and this renders the combination effective. Combinations can also broaden the 
spectrum of species which are targeted. For example, in abdominal sepsis patients, two 
antibiotics such as an aminoglycoside and anti-anaerobe agents are used together to cover as 
many aerobic and anaerobic species of bacteria as possible before the results of microbiological 
tests are available. Some combinations contain drugs which kill dormant organisms(for 
instance pyrazinamide and rifampicin in tuberculosis chemotherapy), thus shortening the 
duration of therapy.  
The advantages of revitalising old antibiotics, such as beta-lactams with a beta-lactamase 
inhibitor, is that the existing antibiotic can be used once again to effectively treat a resistant 
bacterial infection which was previously untreatable by that antibiotic. Further advantages of 
this approach is that it is relatively low cost because one antibiotic resistance breaker can be 
used to rejuvenate several old antibiotics.  In addition the risk which is associated with this 
approach is lower than developing a novel antimicrobial because once the ARB has been shown 
to be safe in clinical trials in combination with one compound, it can be used to rejuvenate 
other old antibiotics. Furthermore, instead of reproducing the Golden era of antibiotic 
discovery by creating 200 novel antibiotics, the world could, potentially, rejuvenate existing 
antibiotics with 20 or less ARBs in combination with 200 existing antibiotics.  
Could ARBs prevent the emergence of resistance? Whilst combinations of drugs are used in 
tuberculosis, HIV and cancer chemotherapy to reduce the emergence of resistance, there are 
certain fundamental differences between these combinations and ARBs for the treatment of 
pyogenic bacterial infections such as urinary tract disease due to Gram-negative bacteria. The 
first difference is that Mycobacterium tuberculosis resistance is not transmitted by plasmids. It 
is chromosomally mediated. This contrasts with resistance in pyogenic bacteria which is 
transmitted by plasmids in some cases, is chromosmally mediated in others and both 
mechanisms in some. It is unlikely that ARBs could reduce the emergence of plasmid mediated 
resistance, but they might be able to impact upon chromosomal resistance. A second important 
difference is that some ARBs, such as some beta-lactamase inhibitors have no anti-bacterial 
activity by themselves. These ARBs are unlikely to be able to prevent even chromosomal 
resistance because resistance emergence is effectively appearing to the one old antibiotic alone. 
If, however, the ARB has some antibacterial activity in its own right, such as HT61 (Hu et al 
2010), mutants which arise to the old antibiotic can be killed by the ARB and thus the 
combination may be able to prevent the emergence of chromosomally mediated resistance. 
Could ARBs be used to reduce the dose of old antibiotics against sensitive bacterial strains, 
and so decrease the incidence of toxic side-effects?  If the ARB can boost the effect of the old 
antibiotic against sensitive strains, it may be possible to use a lower dose of the old antibiotic 
to achieve cure.   
Would ARBs enhance activity against dormant bacteria? This depends upon the ARB. Beta-
lactamase inhibitors have no action against dormant bacteria and so would not increase a beta-
lactam’s activity against dormant bacteria. In contrast, other ARBs such as HT61 which was 
selected for anti-dormancy activity [63,64] boost the activity of the combinations against 
dormant bacteria. 
Historically, resistance has eventually emerged to every antibiotic after entry into the market. 
Clearly, resistance will appear to ARB combinations. Experience with beta-lactamase 
inhibitors suggests that mutant bacteria emerge over time which express beta-lactamases, such 
as the B3a metallo-beta-lactamase  NDM that are resistant to, for example,  clavulanic acid [7]. 
Since bacteria produce over 1000 beta-lactamases, it seems likely that, when challenged with 
a new beta-lactamase inhibitor, mutants will emerge which can neutralise the inhibitor with a 
novel beta-lactamase. Ways need to be found which slow the emergence of resistance. One 
possible route could be to use ARBs which target the cell membrane, on the grounds that it 
may take bacteria longer to develop resistance against combinations which act on the bacterial 
membrane [66].  
ARBs which can rescue old antibiotics from a wide range of resistance challenges are needed, 
and those which can counteract metallo-beta-lactamases are urgently needed.  
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